The STEP-1 body-composition substudy (n=140 DXA cohort) of semaglutide (Wegovy at 2.4 mg weekly) reported fat-free mass loss of approximately 6.9 kg over 68 weeks, accounting for approximately 45% of total weight loss based on the body-composition substudys own arithmetic and the Conte 2024 systematic review [6, 7]
and has different technological characteristics and does not raise different questions of safety and effectiveness
Helpful resources May your spine stay aligned, your discs stay hydrated, and your back pain stay resolved
Some people notice a metallic or off taste, foods they used to love losing their appeal, or Bruising and Injection Site Reactions on Semaglutide Bruising and mild injection site reactions, meaning redness, a small lump, itching, or tenderness, are common with subcutaneous semaglutide and are usually harmless
Huang, Y., Chen, Z., Chen, B., Li, J., Yuan, X., Li, J., Wang, W., Dai, T., Chen, H., Wang, Y., Wang, R., Wang, P., Guo, J., Dong, Q., Liu, C., Wei, Q., Cao, D., & Liu, L
Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation